RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

SAN FRAN­CIS­CO — RTW In­vest­ments is once again pro­vid­ing fund­ing to Ji Xing Phar­ma­ceu­ti­cals, the Shang­hai-based biotech it in­cu­bat­ed in 2019, with $127 mil­lion along­side a $35 mil­lion in­vest­ment from Bay­er’s Leaps by Bay­er unit.

The Se­ries D fi­nanc­ing, dis­closed in the week­end lead­ing up to the JP Mor­gan Health­care Con­fer­ence, could al­so bear fruit for Bay­er’s car­dio­vas­cu­lar and oph­thal­mol­o­gy pipeline, as the multi­na­tion­al Big Phar­ma snags the “priv­i­leged rights to ne­go­ti­ate the com­mer­cial­iza­tion of Ji Xing’s pipeline as­sets” in those broad ar­eas.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER